Columbia researchers have isolated antibodies from COVID-19 patients that neutralize SARS-CoV-2 virus and could be used to treat patients or prevent infections.
Commissioner Adam Silver announced that the NBA will not restart its games although the pandemic is having a huge financial impact on the NBA, there remains too many unknowns to proceed otherwise.
ADARC has taken a leading role in clinical, applied, and basic research related to COVID-19 due to its extensive expertise in COVID-19 virology, clinical treatment, basic research, and drug discovery.
COVID-19 tests are being processed each day by the Clinical Microbiology Lab at New York-Presbyterian/CUIMC to detect the presence of the virus in nasopharyngeal samples to determine infection.
The UK has invested heavily in newly developed home testing kits to test for antibodies to the SARS-CoV-2 virus. At issue is the sensitivity of the test and the levels of antibodies in the population.
Public health experts from China, Japan, Singapore, South Korea, and the U.S. discussed experiences and lessons learned from the front-line responses to COVID-19.
Dr. David Ho had a Q&A with members of the Caltech community to discuss the novel coronavirus and the future of our society in the light of this global pandemic.
Dr. Ho is leading four research teams at Columbia University to identify antivirals as well as monoclonal neutralizing antibodies that may be used to treat and prevent infection with SARS-CoV-2.
New York city is not only the U.S. epicenter of the SARS-CoV-2 pandemic, but it is also on the cutting edge research into understanding and identifying strategies to treat and prevent the infection.
Dr. David Ho, director of the ADARC, talks with Rachel Maddow about the consideration of existing drugs for the treatment of coronavirus infection and the prospects and timeline for an eventual cure.
